He Huang
Abstract
Bortezomib is a new proteasome inhibitor. Clinical studies demonstrat that bortezomib plays role in the treatment for relapsed, refractory and initially treated multiple myeloma. Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Bortezomib is a new proteasome inhibitor. Clinical studies demonstrat that bortezomib plays role in the treatment for relapsed, refractory and initially treated multiple myeloma. Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
Key concepts: Bortezomib, Multiple myeloma, Medicine, Proteasome inhibitor, Oncology, Refractory (planetary science), Proteasome, Internal medicine